CDA C435T gene polymorphism significantly extends the long-term efficacy of gemcitabine in advanced non-small cell lung cancer
10.12092/j.issn.1009-2501.2024.12.003
- VernacularTitle:CDA C435T基因多态性显著延长吉西他滨治疗晚期非小细胞肺癌远期疗效
- Author:
Mengjiao WANG
1
;
Chao GAO
;
Tao WANG
;
Qian ZHANG
;
Juan WEN
;
Dongmei LV
;
Lili HU
Author Information
1. 徐州医科大学药学院,徐州 221000,江苏;徐州医科大学附属医院药学部,徐州 221000,江苏
- Publication Type:Journal Article
- Keywords:
CDA C435T gene;
non-small cell lung cancer;
chemotherapy;
polymorphism;
prognosis
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(12):1337-1343
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To research the effects of cyti-dine deaminase(CDA)C435T polymorphism on the long-term effectiveness of gemcitabine in non-small cell lung cancer(NSCLC).METHODS:Enrolled 145 NSCLC patients received gemcitabine-platinum regiments at the Affiliated Hospital of Xuzhou Med-ical University from August 2016 to February 2019,characteristics recorded such as:age,gender,path-ological type,clinical stage(Ⅰ-ⅢA/ⅢB-Ⅳ)and so on.Followed-up and evaluated according to RECIST1.1,the disease-free survival(DFS),progression-free survival(PFS)and overall survival(OS)was study endpoint.Cases were categorized into wild-type CC and mutant CT/TT group.Kaplan-Meier method and log-rank test were utilized to analyze the rela-tionship between CDA C435T and DFS/PFS/OS.A cox model was implemented to analyze the prog-nostic factors.RESULTS:In stage Ⅰ-ⅢA,median DFS of CT/TT compared with CC was not obvious(16.8 vs.35.7 months,P=0.294),same in median OS(54.3 vs.81.9 months,P=0.256).In stage ⅢB-Ⅳ,the median PFS in CT/TT was longer than CC(10.4 vs.5.0 months,P=0.009),the median OS was undiffer-entiated(16.2 vs.24.3 months,P=0.087).No differ-ence of overall median OS in CC and CT/TT geno-types was seen(21.5 months vs.25.3 months,P=0.077).Cox regression model showed CDA C435T polymorphism was an independent factor of PFS in stage ⅢB-Ⅳ(P=0.019).CONCLUSION:CDA C435T polymorphism shows a function as a prediction in-fluencing PFS of gemcitabine in ⅢB-Ⅳ NSCLC,CT/TT genotype is significantly prolonged.
